| Literature DB >> 34368000 |
Wanpeng Li1, Huankang Zhang1, Hanyu Lu1, Huan Wang1, Yurong Gu1, Houyong Li1, Xicai Sun1, Hongmeng Yu1, Dehui Wang1.
Abstract
BACKGROUND: Salvage endoscopic nasopharyngectomy has better survival prognosis and fewer complications in the management of early stage rNPC, compared to re-irradiation. However, the treatment modality of advanced recurrent nasopharyngeal carcinoma (rNPC) remains controversial. Thus, the purpose of this study was to investigate the demographics, clinical outcomes, and prognostic factors associated with salvage endoscopic nasopharyngectomy in advanced rNPC.Entities:
Keywords: endoscopic; nasopharyngectomy; prognostic factors; recurrent nasopharyngeal carcinoma; survival
Year: 2021 PMID: 34368000 PMCID: PMC8340003 DOI: 10.3389/fonc.2021.716729
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Imaging examination of ICA before and after embolization (A) Horizontal enhanced CT showed that the tumor partially wrapped the left ICA; (B) Coronal enhanced MRI exhibited that the tumor invaded the left pharyngeal recess, parapharyngeal space, the longus capitis, sphenoid body and skull base, and partially surrounded the left ICA; (C, D) Horizontal enhanced CT and coronal enhanced MRI showed the undeveloped cavenous, lacerum, petrous and cervical segments of the left ICA. CT, Computer Tomography; MRI, Magnetic resonance imaging; ICA, Internal carotid artery.
Figure 2Reconstruction of skull base defect after salvage surgery for recurrent nasopharyngeal carcinoma: (A) nasal free flap; (B) septal pedicled flap; and (C) temporal muscle flap. ICA, Internal carotid artery.
Characteristics of patients with advanced rNPC.
| Characteristics | Total = 120 | % |
|---|---|---|
| Gender | ||
| Male | 88 | 73.3 |
| Female | 32 | 26.7 |
| Age (years) | ||
| ≥50 | 65 | 54.2 |
| <50 | 55 | 18.3 |
| Smoking history | ||
| Yes | 30 | 25.0 |
| NO | 90 | 75.0 |
| Drinking history | ||
| Yes | 21 | 17.5 |
| No | 99 | 82.5 |
| Diabetes mellitus | ||
| Yes | 116 | 96.7 |
| No | 4 | 3.3 |
| Hypertension | ||
| Yes | 90 | 75.0 |
| No | 30 | 25.0 |
| BMI | ||
| 18.5–24.9 | 80 | 66.7 |
| <18.5 | 14 | 11.7 |
| >24.9 | 26 | 21.7 |
| Hemoglobin | ||
| ≥120 | 78 | 65.0 |
| <120 | 42 | 35.0 |
| NLR | ||
| ≥6 | 40 | 33.3 |
| <6 | 80 | 66.7 |
| Alkaline phosphatase | ||
| <50 | 6 | 5.0 |
| ≥50 | 114 | 95.0 |
| Period between recurrence and the last session of radiotherapy (year) | ||
| ≥3 | 68 | 56.7 |
| <3 | 52 | 43.3 |
| Preoperative combined chemotherapy | ||
| Yes | 99 | 82.5 |
| No | 21 | 17.5 |
| Histological subtype | ||
| WHO type II | 43 | 35.8 |
| WHO type III | 77 | 64.2 |
| rT stage | ||
| rT3 | 75 | 62.5 |
| rT4 | 45 | 37.5 |
| LNM | ||
| Yes | 28 | 23.3 |
| NO | 92 | 76.7 |
| Tumor necrosis | ||
| Yes | 64 | 53.3 |
| No | 56 | 46.7 |
| Tumor invasion of the ICA | ||
| No invasion | 79 | 65.8 |
| Invasion | 28 | 23.3 |
| Invasion, but ICA was embolized | 13 | 10.8 |
| The use of pedicled flap | ||
| Yes | 55 | 45.8 |
| No | 65 | 54.2 |
| Surgical margin | ||
| Negative margin | 85 | 70.8 |
| Positive margin | 35 | 29.2 |
| Postoperative radiotherapy | ||
| No | 112 | 93.3 |
| Yes | 8 | 6.7 |
| Postoperative chemotherapy | ||
| No | 94 | 78.3 |
| Yes | 26 | 21.7 |
| Postoperative PD-1 treatment | ||
| No | 111 | 92.5 |
| Yes | 9 | 7.5 |
| All patients with follow-up (mean months of survival) | 18 (2-81) | |
| Outcome | ||
| Remission | 39 | 32.5 |
| Deceased | 40 | 33.3 |
| Alive with disease | 41 | 34.2 |
rNPC, recurrent nasopharyngeal carcinoma; BMI, Body mass index; NLR, Neutrophil to lymphocyte ratio; LNM, lymph node metastasis; ICA, Internal carotid artery.
The relationship between surgical margin and ICA embolization in rNPC patients with tumor invasion of ICA.
| Embolization of ICA | Surgical margin | P value | |
|---|---|---|---|
| Negative margin | Positive margin | ||
| No (n) | 15 | 13 | 0.084 |
| Yes (n) | 11 | 2 | |
rNPC, recurrent nasopharyngeal carcinoma; ICA, Internal carotid artery.
Figure 3Kaplan–Meier curve pertaining to the survival in patients with advanced recurrent nasopharyngeal carcinoma: (A) overall survival: and (B) progression-free survival.
Log-rank test of prognostic factors for rNPC.
| Prognostic factors | OS (%) | P value | PFS (%) | P value | ||||
|---|---|---|---|---|---|---|---|---|
| 1-year | 2-year | 3-year | 1-year | 2-year | 3-year | |||
| Sex | 0.110 | 0.640 | ||||||
| Male | 83.5 | 73.8 | 60.4 | 56.9 | 36.0 | 31.4 | ||
| Female | 74.1 | 61.4 | 45.5 | 48.1 | 39.2 | 23.5 | ||
| Age (year) | 0.040 | 0.027 | ||||||
| ≥50 | 74.1 | 54.9 | 45.7 | 46.6 | 27.2 | 21.7 | ||
| <50 | 88.9 | 77.1 | 62.7 | 63.0 | 46.7 | 37.0 | ||
| Smoking history | 0.120 | 0.127 | ||||||
| Yes | 89.3 | 80.3 | 70.3 | 55.6 | 41.1 | 33.2 | ||
| NO | 78.2 | 63.4 | 51.8 | 51.4 | 24.0 | 18.0 | ||
| Drinking history | 0.220 | 0.846 | ||||||
| Yes | 90.5 | 90.5 | 77.6 | 54.1 | 37.1 | 29.8 | ||
| NO | 79.1 | 63.2 | 51.9 | 57.1 | 38.1 | 28.6 | ||
| Diabetes mellitus | 0.926 | 0.815 | ||||||
| Yes | 100 | 50 | 50 | 66.7 | 33.3 | 33.3 | ||
| NO | 80.5 | 67.3 | 55.4 | 54.0 | 37.2 | 29.3 | ||
| Hypertension | 0.847 | 0.670 | ||||||
| Yes | 82.9 | 78.0 | 59.4 | 54.6 | 31.9 | 31.9 | ||
| No | 80.4 | 63.9 | 54.4 | 54.6 | 38.8 | 28.9 | ||
| BMI | <0.001 | 0.004 | ||||||
| 18.5–24.9 | 81.7 | 69.5 | 53.2 | 58.2 | 44.9 | 33.3 | ||
| <18.5 | 57.1 | 32.7 | 16.3 | 35.9 | 0 | 0 | ||
| >24.9 | 92.3 | 92.3 | 92.3 | 54.4 | 34.6 | 34.6 | ||
| Hemoglobin | 0.461 | 0.115 | ||||||
| ≥120 | 81.5 | 67.9 | 57.5 | 59.4 | 41.2 | 33.7 | ||
| <120 | 80.2 | 64.9 | 47.3 | 45.9 | 32.2 | 16.1 | ||
| NLR | 0.137 | 0.644 | ||||||
| ≥6 | 72.5 | 56.1 | 42.1 | 38.7 | 38.7 | 29.0 | ||
| <6 | 83.4 | 70.2 | 58.7 | 59.0 | 36.7 | 29.6 | ||
| Alkaline phosphatase | 0.899 | 0.428 | ||||||
| <50 | 83.3 | 83.3 | 41.7 | 60.0 | 60.0 | 60.0 | ||
| ≥50 | 81.0 | 66.2 | 55.6 | 54.3 | 36.1 | 28.0 | ||
| Preoperative combined chemotherapy | 0.067 | |||||||
| chemotherapy | 0.541 | |||||||
| Yes | 84.1 | 69.2 | 57.4 | 52.4 | 40.7 | 31.6 | ||
| No | 66.7 | 55.6 | 41.7 | 65.9 | 13.8 | 13.8 | ||
| Period between recurrence and the last | ||||||||
| session of radiotherapy (year) | 0.433 | 0.291 | ||||||
| ≥3 | 80.4 | 72.4 | 68.8 | 60.6 | 43.7 | 30.9 | ||
| <3 | 81.8 | 62.9 | 43.2 | 47.9 | 30.6 | 27.2 | ||
| Histological subtype | 0.406 | 0.340 | ||||||
| WHO type II | 73.9 | 63.5 | 57.7 | 59.0 | 44.1 | 35.3 | ||
| WHO type III | 86.6 | 69.2 | 54.5 | 52.2 | 34.1 | 26.0 | ||
| rT stage | 0.001 | 0.020 | ||||||
| rT3 | 88.8 | 75.3 | 68.8 | 63.7 | 43.8 | 40.6 | ||
| rT4 | 68.4 | 53.7 | 36.9 | 41.8 | 28.2 | 15.1 | ||
| LNM | 0.216 | 0.159 | ||||||
| Yes | 78.2 | 60.0 | 40.0 | 55.7 | 28.6 | 14.3 | ||
| No | 81.9 | 69.2 | 60.0 | 54.1 | 40.4 | 33.1 | ||
| Tumor necrosis | 0.001 | 0.698 | ||||||
| Yes | 71.8 | 53.4 | 38.6 | 58.7 | 36.2 | 25.6 | ||
| No | 88.8 | 78.0 | 67.9 | 50.4 | 39.6 | 39.6 | ||
| Tumor invasion of the ICA | <0.001 | 0.192 | ||||||
| No invasion | 89.6 | 79.2 | 65.1 | 57.6 | 39.6 | 34.8 | ||
| Invasion | 49.5 | 23.6 | 15.7 | 39.9 | 23.3 | 11.7 | ||
| Invasion, but ICA was embolized | 100 | 100 | 100 | 68.6 | 57.1 | 28.6 | ||
| The use of pedicled flap | 0.024 | 0.513 | ||||||
| Yes | 92.6 | 77.8 | 60.5 | 50.9 | 33.7 | 23.6 | ||
| No | 71.8 | 58.7 | 50.5 | 57.6 | 40.2 | 34.0 | ||
| Surgical margin | 0.017 | 0.139 | ||||||
| Negative margin | 86.6 | 75.2 | 61.9 | 55.2 | 43.0 | 36.3 | ||
| Positive margin | 67.8 | 50.8 | 41.9 | 53.4 | 25.1 | 15.1 | ||
| Postoperative radiotherapy | 0.655 | 0.200 | ||||||
| No | 81.5 | 68.3 | 55.6 | 56.6 | 38.1 | 29.6 | ||
| Yes | 75.0 | 50.0 | 50.0 | 31.3 | 31.3 | 31.3 | ||
| Postoperative chemotherapy | 0.134 | 0.248 | ||||||
| No | 79.1 | 65.8 | 51.1 | 58.3 | 39.1 | 34.0 | ||
| Yes | 87.7 | 71.7 | 71.7 | 42.4 | 31.4 | 16.7 | ||
| Postoperative PD-1 treatment | 0.238 | 0.675 | ||||||
| No | 79.5 | 66.2 | 53.7 | 54.9 | 38.3 | 32.5 | ||
| Yes | 100 | 83.3 | 83.3 | 51.9 | 25.9 | 25.9 | ||
rNPC, recurrent nasopharyngeal carcinoma; OS, Overall survival; PFS, Progress free survival; BMI, Body mass index; NLR, Neutrophil to lymphocyte ratio; LNM, lymph node metastasis; ICA, Internal carotid artery.
Figure 4Kaplan–Meier curves pertaining to the overall survival in patients with recurrent nasopharyngeal carcinoma: (A) age (≥50 vs. <50 years); (B) body mass index (BMI); (C) rT stage (rT3 vs. rT4); (D) tumor necrosis; (E) tumor invasion into the ICA; (F) the use of pedicled flap; and (G) surgical margins.
Figure 5Kaplan–Meier curves pertaining to the progression-free survival in patients with recurrent nasopharyngeal carcinoma: (A) age (≥50 vs. <50 years); (B) body mass index (BMI); and (C) rT stage (rT3 vs. rT4).
Univariate and multivariate Cox regression analyses of OS in patients with rNPC.
| Variable | Univeriate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | ||
| Age (year) | |||||||
| ≥50 | 1 | Reference | 1 | Reference | |||
| <50 | 0.517 | 0.272-0.985 | 0.045 | 0.462 | 0.235-0.908 | 0.025 | |
| BMI | |||||||
| 18.5–24.9 | 1 | Reference | 1 | Reference | |||
| <18.5 | 3.693 | 1.745-7.817 | 0.001 | 2.981 | 1.282-6.931 | 0.011 | |
| >24.9 | 0.348 | 0.105-1.147 | 0.083 | 0.570 | 0.159-2.047 | 0.388 | |
| T stage | |||||||
| rT3 | 1 | Reference | 1 | Reference | |||
| rT4 | 2.827 | 1.483-5.391 | 0.002 | 2.396 | 1.140-5.037 | 0.021 | |
| Tumor necrosis | |||||||
| Yes | 1 | Reference | 1 | Reference | |||
| No | 0.361 | 0.189-0.688 | 0.002 | 0.488 | 0.249-0.960 | 0.038 | |
| Tumor invaded the ICA | |||||||
| No invasion | 1 | Reference | 1 | Reference | |||
| Invasion | 5.164 | 2.713-9.827 | 0.000 | 2.445 | 1.093-5.469 | 0.030 | |
| Invasion, but ICA was embolized. | <0.001 | / | 0.968 | <0.001 | / | 0.971 | |
| Surgical margin | |||||||
| Negative margin | 1 | Reference | 1 | Reference | |||
| Positive margin | 2.108 | 1.123-3.959 | 0.020 | 1.017 | 0.478-2.162 | 0.965 | |
| The use of pedicled flap | |||||||
| Yes | 1 | Reference | 1 | Reference | |||
| No | 2.179 | 1.085-4.379 | 0.029 | 1.405 | 0.666 -2.968 | 0.372 | |
| Sex | |||||||
| Male | 1 | Reference | |||||
| Female | 1.667 | 0.876-3.171 | 0.119 | ||||
| Smoking history | |||||||
| Yes | 1 | Reference | |||||
| No | 2.064 | 0.805-5.295 | 0.132 | ||||
| Drinking history | |||||||
| Yes | 1 | Reference | |||||
| No | 2.439 | 0.751-7.926 | 0.138 | ||||
| Diabetes mellitus | |||||||
| Yes | 1 | Reference | |||||
| No | 0.911 | 0.124-6.685 | 0.911 | ||||
| Hypertension | |||||||
| Yes | 1 | Reference | |||||
| NO | 0.933 | 0.455-1.910 | 0.849 | ||||
| Hemoglobin | |||||||
| <120 | 1 | Reference | |||||
| ≥120 | 0.783 | 0.405-1.511 | 0.466 | ||||
| NLR | |||||||
| ≥6 | 1 | Reference | |||||
| <6 | 0.593 | 0.294-1.198 | 0.145 | ||||
| Alkaline phosphatase | |||||||
| <50 | 1 | Reference | |||||
| ≥50 | 1.096 | 0.264-4.552 | 0.900 | ||||
| The time between recurrence and the last radiotherapy (year) | |||||||
| ≥3 | 1 | Reference | |||||
| <3 | 1.282 | 0.684-2.405 | 0.438 | ||||
| Preoperative combined chemotherapy before surgery | |||||||
| Yes | 1 | Reference | |||||
| No | 1.922 | 0.937-3.941 | 0.075 | ||||
| Histological subtype | |||||||
| WHO type II | 1 | Reference | |||||
| WHO type III | 0766 | 0.405-1.447 | 0.411 | ||||
| LNM | |||||||
| Yes | 1 | Reference | |||||
| No | 0.657 | 0.334-1.292 | 0.068 | ||||
| Postoperative radiotherapy | |||||||
| No | 1 | Reference | |||||
| Yes | 1.305 | 0.401-4.240 | 0.658 | ||||
| Postoperative chemotherapy | |||||||
| No | 1 | Reference | |||||
| Yes | 0.498 | 0.195-1.273 | 0.145 | ||||
| Postoperative PD-1 treatment | |||||||
| No | 1 | Reference | |||||
| Yes | 0.324 | 0.044-2.366 | 0.267 | ||||
rNPC, recurrent nasopharyngeal carcinoma; OS, Overall survival; BMI, Body mass index; NLR, Neutrophil to lymphocyte ratio; LNM, lymph node metastasis; ICA, Internal carotid artery; HR, hazard ratio; CI, confidence interval.
Figure 6Receiver operating characteristic analysis revealed that the rT stage was the best predictor for overall survival (OS). The area under the ROC curve for rT stage was 0.669 (P = 0.003).
Univariate and multivariate Cox regression analyses of PFS in patients with rNPC.
| Variable | Univeriate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Age (year) | ||||||
| ≥50 | 1 | Reference | 1 | Reference | ||
| <50 | 0.580 | 0.352-0.957 | 0.033 | 0.610 | 0.368-1.010 | 0.055 |
| BMI | ||||||
| 18.5–24.9 | 1 | Reference | 1 | Reference | ||
| <18.5 | 2.795 | 1.445-5.409 | 0.002 | 2.462 | 1.267-4.784 | 0.008 |
| >24.9 | 1.019 | 0.544-1.908 | 0.953 | 0.904 | 0.480-1.703 | 0.755 |
| T stage | ||||||
| rT3 | 1 | Reference | 1 | Reference | ||
| rT4 | 1.750 | 1.075-2.850 | 0.024 | 1.648 | 1.010-2.689 | 0.046 |
| Sex | ||||||
| Male | 1 | Reference | ||||
| Female | 0.881 | 0.511-1.518 | 0.648 | |||
| Smoking history | ||||||
| Yes | 1 | Reference | ||||
| No | 0.662 | 0.384-1.142 | 0.138 | |||
| Drinking history | ||||||
| Yes | 1 | Reference | ||||
| No | 0.849 | 0.477-1.839 | 0.849 | |||
| Diabetes mellitus | ||||||
| Yes | 1 | Reference | ||||
| No | 0.849 | 0.207-3.480 | 0.849 | |||
| Hypertension | ||||||
| Yes | 1 | Reference | ||||
| No | 0.677 | 0.496-1.578 | 0.677 | |||
| Hemoglobin | ||||||
| <120 | 1 | Reference | ||||
| ≥120 | 0.670 | 0.401-1.119 | 0.126 | |||
| NLR | ||||||
| ≥6 | 1 | Reference | ||||
| <6 | 0.872 | 0.482-1.579 | 0.652 | |||
| Alkaline phosphatase | ||||||
| <50 | 1 | Reference | ||||
| ≥50 | 1.732 | 0.424-7.084 | 0.444 | |||
| The time between recurrence and the | ||||||
| last radiotherapy (year) | ||||||
| ≥3 | 1 | Reference | ||||
| <3 | 1.292 | 0.794-2.101 | 0.303 | |||
| Preoperative combined chemotherapy before surgery | ||||||
| Yes | 1 | Reference | ||||
| No | 1.211 | 0.645-2.275 | 0.551 | |||
| Histological subtype | ||||||
| WHO type II | 1 | Reference | ||||
| WHO type III | 1.289 | 0.755-2.200 | 0.353 | |||
| LNM | ||||||
| Yes | 1 | Reference | ||||
| No | 0.688 | 0.402-1.175 | 0.171 | |||
| Postoperative radiotherapy | ||||||
| No | 1 | Reference | ||||
| Yes | 0.559 | 0.223-1.402 | 0.215 | |||
| Postoperative chemotherapy | ||||||
| No | 1 | Reference | ||||
| Yes | 1.374 | 0.790-2.390 | 0.261 | |||
| Postoperative PD-1 treatment | ||||||
| No | 1 | Reference | ||||
| Yes | 0.839 | 0.361-1.947 | 0.683 | |||
| Tumor necrosis | ||||||
| Yes | 1 | Reference | ||||
| No | 0.910 | 0.558-1.483 | 0.705 | |||
| Tumor invaded the ICA | ||||||
| No invasion | 1 | Reference | ||||
| Invasion | 1.554 | 0.888-2.718 | 0.122 | |||
| Invasion, but ICA was embolized. | 0.774 | 0.306-1.959 | 0.589 | |||
| Surgical margin | ||||||
| Negative margin | 1 | Reference | ||||
| Positive margin | 1.444 | 0.875-2.383 | 0.150 | |||
| The use of pedicled flap | ||||||
| Yes | 1 | Reference | ||||
| No | 0.853 | 0.523-1.391 | 0.853 | |||
rNPC, recurrent nasopharyngeal carcinoma; PFS, progress free survival; BMI, Body mass index; NLR, Neutrophil to lymphocyte ratio; LNM, lymph node metastasis; ICA, Internal carotid artery; HR, hazard ratio; CI, confidence interval.